Camp4 Therapeutics Corp 8-K

What Happened

• Camp4 Therapeutics Corp. (CAMP) announced that its Board appointed Michael MacLean as a Class III director, effective April 1, 2026. The Board increased its size from eight to nine members. The appointment and board action were approved on March 18, 2026 and reported in an 8‑K filed March 24, 2026.
• Mr. MacLean will join the Board’s Audit Committee and Compensation Committee and will enter into the company’s standard director indemnification agreement.

Key Details

• Appointment effective date: April 1, 2026; Board approval date: March 18, 2026; 8‑K filed March 24, 2026.
• New Board size: increased from 8 to 9 directors.
• Equity compensation: Mr. MacLean will be granted an option to purchase 56,000 shares under the 2024 Equity Incentive Plan; the option vests monthly over three years.
• Cash compensation: he will receive the cash retainers provided under the amended Non‑Employee Director Compensation Policy for Board, Audit Committee, and Compensation Committee service.
• Background: Mr. MacLean, age 60, has 35+ years in finance and life sciences; most recently CFO of Avidity Biosciences (May 2020–April 2026), prior CFO roles at Akcea Therapeutics and PureTech Health, senior finance roles at Biogen, and a former Big Four audit partner. He served on Verve Therapeutics’ board (2021–2025).
• Independence/transactions: No arrangements with other persons led to his appointment; he had no transactions with Camp4 exceeding $120,000 since the start of the last fiscal year.

Why It Matters

• The company highlights Mr. MacLean’s public company CFO and finance experience as qualifying him for the Board role; his placement on the Audit Committee may strengthen oversight of financial reporting and controls given his background (as stated in the filing).
• The Board expansion and the amended director compensation policy create a specific equity grant (56,000‑share option) for new non‑employee directors appointed on or after the appointment date, which is a concrete change to director pay and future share-based awards investors may want to note.